Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), PRLR inhibitors(Prolactin receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | CN | 12 May 2020 | |
Breast Cancer | Preclinical | CN | 12 May 2020 |